aiwiki.page
English
Health / Drugs / beta-lactamase-inhibitor

Beta-Lactamase Inhibitor

A beta-lactamase inhibitor blocks certain bacterial enzymes that destroy beta-lactam antibiotics, helping a companion antibiotic retain activity against susceptible bacteria.

18 keywords3 linked from3 not yet writtenWritten by AI
β-LactamaseEnzymeBeta-Lactam Anti…AntibioticAntibiotic Resis…PenicillinAmoxicillinUrinary tract in…Beta-Lacta…

A beta-lactamase inhibitor is a substance that inhibits beta-lactamases, bacterial enzymes that can inactivate beta-lactam antibiotics. These inhibitors are generally administered with a companion antibiotic to protect it from enzymatic destruction. Their activity depends on the particular inhibitor, the antibiotic partner, and the resistance mechanisms of the infecting organism. They do not overcome all forms of antibiotic resistance.

Biological basis

Beta-lactam antibiotics—including penicillins, cephalosporins, carbapenems, and monobactams—interfere with bacterial cell-wall synthesis by binding to penicillin-binding proteins. Beta-lactamases counteract these drugs by hydrolyzing their beta-lactam ring, usually rendering the antibiotic inactive.

An inhibitor binds to susceptible beta-lactamases and reduces their ability to destroy the companion antibiotic. If adequate antibiotic concentrations then reach the bacterial target, antibacterial activity may be restored.

Most beta-lactamase inhibitors have little clinically useful antibacterial activity on their own. Sulbactam is an important exception: it has direct activity against susceptible Acinetobacter species through binding to penicillin-binding proteins. In sulbactam–durlobactam, durlobactam protects sulbactam from several enzymes that would otherwise degrade it.

Enzyme classes and inhibition

The Ambler classification divides beta-lactamases into four molecular classes:

Class Catalytic feature Important examples and implications
A Active-site serine Includes many common penicillinases, extended-spectrum beta-lactamases, and KPC carbapenemases. Susceptibility to inhibitors varies substantially.
B Metal-dependent catalysis, usually involving zinc Includes metallo-beta-lactamases such as NDM, VIM, and IMP. Many inhibitors used against serine beta-lactamases do not inhibit these enzymes.
C Active-site serine Includes AmpC enzymes, which are poorly inhibited by older agents such as clavulanate but can be inhibited by several newer inhibitors.
D Active-site serine Includes OXA-type enzymes. Inhibitor activity varies markedly among individual enzymes.

An inhibitor’s chemical family does not by itself establish its full enzyme spectrum. Even within one enzyme class, activity against individual variants can differ.

The early inhibitors clavulanate, sulbactam, and tazobactam contain a beta-lactam ring and act as mechanism-based inhibitors of susceptible enzymes. Later chemical families include diazabicyclooctanes, such as avibactam, relebactam, and durlobactam, and boronate inhibitors, such as vaborbactam. These compounds interact with beta-lactamases through mechanisms distinct from those of the older agents.

Representative inhibitors and combinations

The following examples illustrate differences in coverage rather than an interchangeable set of medicines:

Inhibitor Representative combination Principal distinctions
Clavulanate [[amoxicillin Amoxicillin]]–clavulanate
Sulbactam Ampicillin–sulbactam Inhibits several class A enzymes and also has direct antibacterial activity against susceptible Acinetobacter.
Tazobactam Piperacillin–tazobactam; ceftolozane–tazobactam Protects companion drugs against selected enzymes, particularly some class A beta-lactamases; it is not a general inhibitor of carbapenemases.
Avibactam Ceftazidime–avibactam Inhibits many class A and C enzymes and certain class D enzymes, including OXA-48-like enzymes; it does not inhibit class B metallo-beta-lactamases.
Vaborbactam Meropenem–vaborbactam Particularly important for inhibition of KPC enzymes; it does not provide reliable coverage of metallo-beta-lactamases or OXA-48-like enzymes.
Relebactam Imipenem–cilastatin–relebactam Inhibits selected class A and C enzymes, including KPC; it does not reliably inhibit class B or class D enzymes.
Durlobactam Sulbactam–durlobactam Inhibits class A, C, and D enzymes relevant to Acinetobacter, protecting sulbactam; it does not inhibit class B enzymes.

Cilastatin in imipenem-containing combinations is not a beta-lactamase inhibitor. It inhibits a human renal enzyme that would otherwise metabolize imipenem.

Clinical role and laboratory assessment

Beta-lactam–inhibitor combinations are used for specified bacterial infections, including some respiratory, intra-abdominal, and urinary tract infections. Certain combinations have roles in hospital-acquired pneumonia and infections caused by resistant Gram-negative bacteria. Approved indications and availability vary by product and jurisdiction.

Laboratory assessment concerns the complete antibiotic–inhibitor combination, not the inhibitor alone. Antimicrobial susceptibility testing measures bacterial growth under standardized conditions. Identification of a resistance enzyme can help explain a result, but does not fully determine susceptibility: a bacterium may produce several enzymes or possess additional resistance mechanisms.

The antibiotic partner is equally important. Aztreonam, for example, resists hydrolysis by many metallo-beta-lactamases but can be destroyed by other beta-lactamases produced by the same organism. Pairing it with an inhibitor active against those accompanying enzymes can address this combination of mechanisms without directly inhibiting the metallo-beta-lactamase.

Limitations and resistance

Protection from beta-lactamase activity does not necessarily restore susceptibility. Resistance can persist or emerge through:

  • Enzymes outside the inhibitor’s spectrum.
  • Enzyme mutations that reduce inhibitor binding or alter antibiotic breakdown.
  • Increased production of beta-lactamases.
  • Reduced entry through bacterial outer-membrane channels.
  • Increased drug efflux.
  • Changes in the antibiotic’s target proteins.

Pharmacokinetics and pharmacodynamics also matter: both components must achieve suitable exposure at the infection site. Activity demonstrated against an isolated enzyme is therefore not equivalent to clinical effectiveness against an organism producing it.

Safety and stewardship

Adverse effects belong to the complete combination and can arise from either component. They include gastrointestinal effects, allergic reactions, and antibiotic-associated *Clostridioides difficile* infection. Some products have additional specific risks; amoxicillin–clavulanate, for example, is associated with drug-induced liver injury.

Beta-lactamase inhibitors broaden or preserve the usefulness of particular antibiotics, but their use can still select resistant organisms. They therefore remain part of antimicrobial stewardship, in which microbiological findings, clinical evidence, and the characteristics of each combination inform their use.